Trial · NCT04288232
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
NCT04288232, Phase 3, Completed, Taipei Veterans General Hospital, Taiwan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan. Trials, record NCT04288232. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04288232
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
- NCT number
- NCT04288232
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 45 participants, actual
- Lead sponsor
- Taipei Veterans General Hospital, Taiwan
- Conditions
- Center-involved Diabetic Macular Edema
- Interventions
- Aflibercept Injection [Eylea]
- First posted
- 2020-02-28
- Last updated
- 2020-02-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change of best corrected visual acuity (BCVA) from baseline to week 52 | baseline to week 52 | BCVA is measured by ETDRS chart |
| Secondary | Mean change in central subfoveal thickness (CST) from baseline to week 52. | baseline to week 52 | Central subfoveal thickness (CST) as assessed by OCT |
| Secondary | Mean/medium number of injection from baseline to week 52 | baseline to week 52 | Mean/medium number of intravitreal aflibercept injection from baseline to week 52 |
| Secondary | Proportion of subjects who gained > 15 ETDRS letters from baseline to week 52 | baseline to week 52 | BCVA is measured by ETDRS chart |
| Secondary | Proportion of subjects with > 2-step improvement in DRSS from baseline to week 52 | baseline to week 52 | DR level as assessed by diabetic retinopathy severity score (DRSS) |
| Secondary | Proportion of subjects demonstrating retina dry at week 20 and week 52 | week 20 and week 52 | Retina dry as assessed by OCT |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04288232
GET https://conductscience.org/api/trials/v1/NCT04288232/papers?page=2